These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 18977047)
1. The challenges of regulating stem cell-based products. von Tigerstrom BJ Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047 [TBL] [Abstract][Full Text] [Related]
2. Legal and ethical status of stem cells as medicinal products. Tsang L Adv Drug Deliv Rev; 2005 Dec; 57(13):1970-80. PubMed ID: 16297498 [TBL] [Abstract][Full Text] [Related]
4. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics. Lodén M; Ungerth L; Serup J Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885 [TBL] [Abstract][Full Text] [Related]
5. Switzerland: one year's experience with new regulations and a new agency. Voelksen R Med Device Technol; 2003 Mar; 14(2):28-9. PubMed ID: 12698697 [TBL] [Abstract][Full Text] [Related]
6. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU. Brévignon-Dodin L Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319 [TBL] [Abstract][Full Text] [Related]
7. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union. Vlietinck A; Pieters L; Apers S Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891 [TBL] [Abstract][Full Text] [Related]
8. Stem cells. U.S. regulation of stem cells as medical products. Sipp D; Turner L Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541 [No Abstract] [Full Text] [Related]
9. US and European postmarket clinical data requirements. Donawa M Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495 [TBL] [Abstract][Full Text] [Related]
10. [The use of nanotechnology in medicinal products in the light of European Union law]. Jurewicz M Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580 [TBL] [Abstract][Full Text] [Related]
11. Consumer exposure scenarios: development, challenges and possible solutions. Van Engelen JG; Heinemeyer G; Rodriguez C J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S26-33. PubMed ID: 17505503 [TBL] [Abstract][Full Text] [Related]
13. Manufacturing considerations for clinical uses of therapies derived from stem cells. Weber DJ Methods Enzymol; 2006; 420():410-30. PubMed ID: 17161709 [TBL] [Abstract][Full Text] [Related]
14. Legal aspects of E-HEALTH. Callens S; Cierkens K Stud Health Technol Inform; 2008; 141():47-56. PubMed ID: 18953124 [TBL] [Abstract][Full Text] [Related]
15. Stem cell transplantation and ethics: a European overview. Holm S Fetal Diagn Ther; 2004; 19(2):113-8. PubMed ID: 14764952 [TBL] [Abstract][Full Text] [Related]
16. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products]. Reiss M; Büttel IC; Schneider CK Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535 [TBL] [Abstract][Full Text] [Related]
17. European drug regulation--anti-protectionism or consumer protection? Lancet; 1991 Jun; 337(8757):1571-2. PubMed ID: 1675711 [No Abstract] [Full Text] [Related]
18. Australian and New Zealand governments agree to proceed with the joint regulatory agency for therapeutic products. Moore J J Law Med; 2011 Dec; 19(2):272-4. PubMed ID: 22320002 [No Abstract] [Full Text] [Related]
19. EU borderline cosmetic products review of current regulatory status. Morganti P; Paglialunga S Clin Dermatol; 2008; 26(4):392-7. PubMed ID: 18691521 [TBL] [Abstract][Full Text] [Related]
20. European medical device regulation: a new era? Donawa M Med Device Technol; 2004 Dec; 15(10):30-1. PubMed ID: 16225282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]